{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:42:23Z","timestamp":1781797343322,"version":"3.54.5"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.0380","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:34:23Z","timestamp":1614702863000},"page":"e210380","source":"Crossref","is-referenced-by-count":17,"title":["Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs"],"prefix":"10.1001","volume":"4","author":[{"given":"Amanda Katherina","family":"Herbrand","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"Department of Internal Medicine, St Claraspital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ewald","sequence":"additional","affiliation":[{"name":"Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"University Medical Library, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Goldkuhle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Diem","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland"},{"name":"Department of Oncology and Hematology, Spital Grabs, Grabs, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Hoogkamer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Moffa","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars G.","family":"Hemkens","sequence":"additional","affiliation":[{"name":"Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"Meta-Research Innovation Center Berlin (METRICS-B), Berlin Institute of Health, Berlin, Germany"},{"name":"Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kasenda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"Research and Development, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"7","key":"zoi210025r1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jama.297.7.683","article-title":"Experts weigh in on promotion, prescription of off-label drugs.","volume":"297","author":"Hampton","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"zoi210025r2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jcpt.2017.42.issue-3","article-title":"Off-label drug use in oncology: a systematic review of literature.","volume":"42","author":"Saiyed","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"zoi210025r3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/JCO.2012.42.7252","article-title":"Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.","volume":"31","author":"Conti","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi210025r4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00228-014-1662-5","article-title":"Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.","volume":"70","author":"Joerger","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"zoi210025r5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off-label drug use\u2014rethinking the role of the FDA.","volume":"358","author":"Stafford","year":"2008","journal-title":"N Engl J Med"},{"key":"zoi210025r6","doi-asserted-by":"publisher","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi210025r7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"issue":"18","key":"zoi210025r8","article-title":"Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer.","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210025r10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/annonc\/mdn603","article-title":"Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.","volume":"20","author":"McCabe","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi210025r12","first-page":"428","article-title":"Off-label drug information: regulation, distribution, evaluation, and related controversies.","volume":"34","author":"Ventola","year":"2009","journal-title":"P T"},{"issue":"6","key":"zoi210025r13","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000596","article-title":"Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.","volume":"4","author":"Herbrand","year":"2019","journal-title":"ESMO Open"},{"key":"zoi210025r16","doi-asserted-by":"publisher","first-page":"d2090","DOI":"10.1136\/bmj.d2090","article-title":"How to obtain the confidence interval from a P value.","volume":"343","author":"Altman","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"zoi210025r17","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1002\/hec.v27.1","article-title":"State insurance mandates and off-label use of chemotherapy.","volume":"27","author":"Smieliauskas","year":"2018","journal-title":"Health Econ"},{"key":"zoi210025r18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fphar.2019.01210","article-title":"The off-label use of antineoplastics in oncology is limited but has notable scientific support in a university hospital setting.","volume":"10","author":"Herrero Fernandez","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"zoi210025r20","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.3747\/co.23.2803","article-title":"Cross-comparison of cancer drug approvals at three international regulatory agencies.","volume":"23","author":"Samuel","year":"2016","journal-title":"Curr Oncol"},{"issue":"12","key":"zoi210025r21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/annonc\/mdz455","article-title":"When is off-label off-road?","volume":"30","author":"de Vries","year":"2019","journal-title":"Ann Oncol"},{"key":"zoi210025r22","doi-asserted-by":"publisher","first-page":"k668","DOI":"10.1136\/bmj.k668","article-title":"Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.","volume":"360","author":"Wagner","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"zoi210025r23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians.","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9209","key":"zoi210025r24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"23","key":"zoi210025r25","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi210025r26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"issue":"23","key":"zoi210025r27","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5-6","key":"zoi210025r28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000501562","article-title":"Access to Cancer Precision Medicines in Switzerland: A Comparative Analysis (USA and EU) and Health Policy Implications.","volume":"21","author":"Vokinger","year":"2018","journal-title":"Public Health Genomics"},{"key":"zoi210025r30","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"zoi210025r31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration.","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"zoi210025r9","unstructured":"Food and Drug Administration. Herceptin (trastuzumab). Accessed March 9, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/103792s5250ltr.pdf"},{"key":"zoi210025r11","unstructured":"Der Bundesrat. Verordnung \u00fcber die Krankenversicherung. Accessed March 9, 2020. https:\/\/www.admin.ch\/opc\/de\/classified-compilation\/19950219\/index.html#id-1-4-3-4a"},{"key":"zoi210025r14","unstructured":"refdata. Arzneimittelinformation. Accessed April 17, 2020. https:\/\/www.swissmedicinfo.ch\/Accept.aspx?ReturnUrl=%2f"},{"key":"zoi210025r15","unstructured":"Swissmedic. Swissmedic Journal. Accessed February 19, 2020. https:\/\/www.swissmedic.ch\/swissmedic\/de\/home\/ueber-uns\/publikationen\/swissmedic-journal.html"},{"key":"zoi210025r19","unstructured":"Weda? M, Hoebert? J, Vervloet? M, . Study on off-label use of medicinal products in the European Union. Accessed February 19, 2020. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/documents\/2017_02_28_final_study_report_on_off-label_use_.pdf"},{"key":"zoi210025r29","unstructured":"National Institute for Cancer Epidemiology, Registration. Nationales Institut f\u00fcr Krebsepidemiologie und -registrierung, Schweiz. Accessed January 27, 2021. https:\/\/www.nkrs.ch\/de\/stat\/die-statistiken-zur-nationalen-krebsinzidenz\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2776927\/herbrand_2021_oi_210025_1613747271.44277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:34:41Z","timestamp":1614702881000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2776927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0380","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}